<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 72-year-old female negative for <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B surface antigen (HBsAg) and positive for antibody to <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B surface antigen (anti-HBs) was diagnosed to have follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in 2006 </plain></SENT>
<SENT sid="1" pm="."><plain>Seventeen cycles of rituximab-based chemotherapy were administered over 23 months </plain></SENT>
<SENT sid="2" pm="."><plain>Twelve days after the last cycle of chemotherapy, serum aminotransferase levels were elevated, and <z:hpo ids='HP_0012115'>hepatitis</z:hpo> serology tests revealed reappearance of HBsAg and <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B e antigen (HBeAg), loss of anti-HBs, and positivity for <z:hpo ids='HP_0012115'>hepatitis</z:hpo> B virus (HBV) DNA </plain></SENT>
<SENT sid="3" pm="."><plain>Antiviral treatment with entecavir was administered immediately, and the <z:hpo ids='HP_0012115'>hepatitis</z:hpo> flare was controlled </plain></SENT>
<SENT sid="4" pm="."><plain>Rituximab-based chemotherapy can induce HBV reactivation even in HBsAg-negative, anti-HBs-positive patients </plain></SENT>
<SENT sid="5" pm="."><plain>Early recognition and prompt antiviral treatment is crucial for patients with HBV reactivation during anticancer therapy </plain></SENT>
</text></document>